Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr 22:7:140.
doi: 10.12688/wellcomeopenres.17869.1. eCollection 2022.

Human infection studies: Key considerations for challenge agent development and production

Shobana Balasingam  1 , Sarah Meillon  1 , Cecilia Chui  2 , Alex Mann  3 , Carine La  3 , Charlotte L Weller  1 , Deborah F King  1 , Emma Smith  4
Affiliations
Editorial

Human infection studies: Key considerations for challenge agent development and production

Shobana Balasingam et al. Wellcome Open Res. .

Abstract

Human infection (or challenge) studies involve the intentional administration of a pathogen (challenge agent) to volunteers. The selection, isolation, development and production of the challenge agent is one of the first steps in developing a challenge study and critical for minimising the risk to volunteers. Regulatory oversight for this production differs globally. Manufacturing agents within a Good Manufacturing Practice (GMP) facility reduces the risk of the manufacturing process by including processes such as confirming the identity of the challenge agent and ascertaining that it's pure and free from impurities. However, in some cases it's not possible or feasible to manufacture to GMP standards, for example where the challenge agent requires an intermediate vector for growth. There is lack of clear guidance on what the minimum requirements for high-quality safe manufacture outside of GMP facilities should be and here we describe the development of a considerations document for the selection and production of challenge agents to meet this need.

Keywords: GMP; challenge agent production; challenge agents; human challenge study; human infection study.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.

References

    1. Talaat KR, Alaimo C, Martin P, et al. : Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection. EBioMedicine. 2021;66:103310. 10.1016/j.ebiom.2021.103310 - DOI - PMC - PubMed
    1. Mackman RL, Sangi M, Sperandio D, et al. : Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015;58(4):1630–43. 10.1021/jm5017768 - DOI - PubMed
    1. Hodgson SH, Juma E, Salim A, et al. : Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol. 2014;5:686. 10.3389/fmicb.2014.00686 - DOI - PMC - PubMed
    1. Roestenberg M, Hoogerwerf MA, Ferreira DM, et al. : Experimental infection of human volunteers. Lancet Infect Dis. 2018;18(10):e312–e22. 10.1016/S1473-3099(18)30177-4 - DOI - PubMed
    1. Day N: Identifier NCT04083508, Vivax Malaria Human Infection Studies in Thailand (MIST1) ClinicalTrials.gov: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US).2019. Reference Source

Publication types

LinkOut - more resources